巴瑞替尼治疗斑秃患者眉毛与睫毛受累的整合分析
基于BRAVE-AA1和BRAVE-AA2两项随机双盲安慰剂对照试验的整合数据,评估斑秃患者眉毛/睫毛受累的基线特征及巴瑞替尼52周疗效。基线时眉毛/睫毛受累越重,头皮脱发越重(平均SALT评分70.6至96.0)。第36周巴瑞替尼2mg和4mg组眉毛/睫毛应答率显著高于安慰剂,且眉毛与睫毛应答高度一致。
要点
- 基线眉毛/睫毛受累程度与头皮脱发严重度平行。
- 巴瑞替尼2mg和4mg在第36周眉毛/睫毛应答率均显著优于安慰剂。
- 第52周头皮应答者中多数同时获得眉毛和睫毛应答。
核心结论
- 基线眉毛/睫毛受累严重度与头皮脱发严重度平行。
- 巴瑞替尼在多数第52周头皮应答者中实现三个毛发部位的整体应答。
研究设计与样本
- BRAVE-AA1(NCT03570749)和BRAVE-AA2(NCT03899259)为随机双盲安慰剂对照试验,在10个国家169个中心开展。
- 患者随机接受安慰剂、巴瑞替尼2mg或4mg,纳入持续治疗至第52周的汇总数据。
主要发现
- 基线时眉毛/睫毛无间隙至完全缺失的患者平均SALT评分范围为70.6至96.0。
- 第36周眉毛应答率(ClinRO 0,1且改善≥1分):巴瑞替尼2mg组28.2%(OR 3.27),4mg组44.3%(OR 6.84),安慰剂组12.6%。
- 第36周睫毛应答率:巴瑞替尼2mg组25.1%(OR 2.95),4mg组46.4%(OR 8.21),安慰剂组12.4%。
- 巴瑞替尼4mg组中约80%在一个部位获毛发再生的患者另一部位也获再生。
- 第52周头皮应答者(SALT≤20)中,巴瑞替尼4mg组78.5%(95/121)获眉毛应答、82.6%(100/121)获睫毛应答、71.1%(86/121)获两者应答。
关键数值与推荐
- 眉毛/睫毛应答定义为ClinRO评分0或1且较基线改善≥1分。
- 头皮应答定义为第52周SALT评分≤20。
临床怎么用
- 评估斑秃严重度时应纳入眉毛和睫毛受累情况。
- 巴瑞替尼治疗可同时改善头皮、眉毛和睫毛毛发再生,治疗目标应覆盖所有受累部位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eyebrow and eyelash (EB/EL) involvement is an important consideration in the assessment of alopecia areata (AA) severity. OBJECTIVES: To report on the integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259), characterizing EB/EL involvement at baseline in patients with AA and response to baricitinib treatment. METHODS: BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) were randomized double-blind placebo-controlled trials conducted at 169 centres in 10 countries. Patients were randomized to placebo, baricitinib 2 mg or baricitinib 4 mg. Pooled data from patients continually treated with baricitinib through week 52 were included. Outcomes were assessed using a clinician-reported outcome (ClinRO) measure for EB/EL and Severity of Alopecia Tool (SALT) score for the scalp. RESULTS: At baseline, patients with more severe EB/EL involvement had more severe scalp hair loss, with mean SALT scores ranging from 70.6 to 96.0 for patients with no gaps to complete absence of hair, respectively, at EB/EL sites. EB/EL response rates [ClinRO (0,1) with ≥ 1-point improvement] at week 36 were significantly higher in patients treated with baricitinib 2 mg [EB: 28.2%, odds ratio (OR) 3.27; EL: 25.1%, OR 2.95] and baricitinib 4 mg (EB: 44.3%, OR 6.84; EL: 46.4%, OR 8.21) compared with placebo (EB: 12.6%; EL: 12.4%). There was high concordance between EB response and EL response, with approximately 80% of patients who achieved hair regrowth at one site achieving regrowth at the other, with baricitinib 4 mg. Among scalp responders (SALT score ≤ 20 at week 52), 78.5% (n = 95/121) and 82.6% (n = 100/121) achieved an EB and EL response, respectively, and 71.1% (n = 86/121) of patients achieved EB and EL responses with baricitinib 4 mg. Among scalp nonresponders (SALT score > 20 at week 52), 46.7% (n = 91/195) and 48.7% (n = 95/195) achieved EB and EL responses, respectively, and 35.4% (n = 69/195) achieved responses in both EB and EL. Similar trends but lower response rates were observed with baricitinib 2 mg. CONCLUSIONS: Baseline severity of EB/EL involvement paralleled that of the scalp. Baricitinib was efficacious in achieving a holistic response across all three hair-bearing sites in the majority of week-52 scalp responders. These data detail the benefits of baricitinib across important hair-bearing sites involved in AA and highlight that individual patient treatment success should account for the totality of the clinical presentation. Alopecia areata (‘AA’ for short) is hair loss caused by the body’s immune system attacking hair follicles by mistake. Hair follicles are the areas where hairs develop. The condition usually occurs on the scalp. However, AA can also affect other body sites such as the eyebrows and eyelashes. This can add to the severity and burden of the disease for people living with the condition. In this study, we wanted to understand how eyebrow and eyelash involvement affects the severity of AA. We also wanted to find out how treatment with a drug called ‘baricitinib’ might help. We combined the results of two previous clinical trials. These trials included patients with AA from 169 treatment centres in 10 countries. In these trials, patients received either a placebo (a ‘dummy drug’) or baricitinib. We found that patients with more severe eyebrow and eyelash loss also had more severe hair loss on their scalp at the start of the study. Seven per cent of patients taking 4 milligrams of baricitinib saw improvement in their eyebrows by week 8. Even more patients (11%) taking the same dose of baricitinib saw improvement in their eyelashes in the same period. By week 52 of the study, more than half of patients had eyebrow and eyelash regrowth. Most patients (71%) who had a lot of hair regrowth on their scalp also found their eyebrows and eyelashes regrew. Even patients who did not have their scalp hair regrow had success with regrowth of their eyebrows and eyelashes. We concluded that eyebrow and eyelash involvement was linked to the severity of scalp hair loss at the start of the study. Treatment with baricitinib resulted in significant regrowth of eyebrows and eyelashes. Many patients experienced regrowth of hair on their scalp, as well as their eyebrows and eyelashes. Our findings will help doctors set better treatment goals for people with AA, focusing on all areas of hair loss.
引用
- Mostaghimi A, Craiglow B, King B, et al. Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib. Br J Dermatol. 2025. PMID: 40179237. doi:10.1093/bjd/ljaf088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。